The addition of mitazalimab to mFOLFIRINOX led to an objective response rate (ORR) of 52% as first-line therapy in 23 patients with metastatic pancreatic cancer, according to findings from a pre-planned interim analysis of the phase 2 OPTIMIZE trial -1 (NCT04888312).1 In a previous study, treatment with FOLFIRINOX led to an ORR of 31.6% in […]
Mitazalimab Plus mFOLFIRINOX enhances responses in previously untreated metastatic pancreatic cancer
After frontline treatment with mitazalimab and mFOLFIRINOX, patients with metastatic pancreatic cancer achieved an objective response rate (ORR) of 52%, according to data from a pre-planned interim analysis of 23 patients enrolled in the Phase 1 study. 2 OPTIMIZE-1 (NCT04888312).1 In a previous study, treatment with FOLFIRINOX led to an ORR of 31.6% in a […]